Trend in breast cancer mortality by intensity (doses/year) of post-diagnostic statin use.

<p>Nationwide cohort of all female breast cancer patients in Finland during 1995–2003.</p

Breast cancer-specific and overall mortality by current pre-diagnostic and post-diagnostic use of specific statins.

<p>Cohort of all breast cancer patients diagnosed in Finland during 1995–2003.</p><p>*Statin types are not mutually exclusive, i.e. person who has used two types of statins (e.g. atorvastatin and simvastatin) is counted as a user in both categories.</p>†<p>Calculated with Cox regression model adjusted for age, tumor stage and morphology, treatment selection and pre-diagnostic statin use.</p><p>Breast cancer-specific and overall mortality by current pre-diagnostic and post-diagnostic use of specific statins.</p

Baseline population characteristics of all breast cancer cases diagnosed in Finland during 1995–2003.

a<p>Any pre-diagnostic or post-diagnostic use.</p>b<p>Age cutoffs selected to reflect menopausal status of the majority of women at breast cancer diagnosis.</p><p>Baseline population characteristics of all breast cancer cases diagnosed in Finland during 1995–2003.</p

Risk of breast cancer death by amount, duration and intensity of post-diagnostic statin use compared to non-users in a cohort of all breast cancer cases diagnosed in Finland during 1995–2003.

a<p>Calculated with Cox regression model adjusted for age, tumor stage and morphology, treatment selection and pre-diagnostic statin use.</p><p>DDD = Defined Daily Dose.</p><p>Risk of breast cancer death by amount, duration and intensity of post-diagnostic statin use compared to non-users in a cohort of all breast cancer cases diagnosed in Finland during 1995–2003.</p

Trend in breast cancer mortality by intensity (doses/year) of pre-diagnostic statin use.

<p>Nationwide cohort of all female breast cancer patients in Finland during 1995–2003.</p

Overall risk of death among post-diagnostic and pre-diagnostic statin users compared to non-users.

<p>Cohort of all breast cancer patients diagnosed in Finland during 1995–2003.</p><p>*Calculated with Cox regression model adjusted for age, tumor stage and morphology and treatment selection.</p><p>DDD = Defined Daily Dose.</p><p>Overall risk of death among post-diagnostic and pre-diagnostic statin users compared to non-users.</p

Risk of breast cancer death by amount, years and intensity of post-diagnostic statin use as compared to non-users.

<p>Statin users limited to new post-diagnostic users only.</p>a<p>Calculated with Cox regression model adjusted for age, tumor stage and morphology and treatment selection.</p><p>DDD = Defined Daily Dose.</p><p>Risk of breast cancer death by amount, years and intensity of post-diagnostic statin use as compared to non-users.</p

Risk of breast cancer death by current pre-diagnostic and post-diagnostic statin use within a cohort of all breast cancer patients diagnosed in Finland during 1995–2003.

<p>Analysis stratified by propensity for post-diagnostic statin use, population characteristics at baseline and primary treatment selection.</p>a<p>Calculated with Cox regression model adjusted for age, tumor stage and morphology and treatment selection.</p>b<p>Propensity for post-diagnostic statin usage as a function of age, tumor stage and morphology, initial treatment choice and pre-diagnostic statin use.</p><p>Risk of breast cancer death by current pre-diagnostic and post-diagnostic statin use within a cohort of all breast cancer patients diagnosed in Finland during 1995–2003.</p

Overall cancer cancer mortality by NSAID current use versus non-use stratified by patient characteristics in the Finnish Prostate Cancer Screening Trial.

<p>Overall cancer cancer mortality by NSAID current use versus non-use stratified by patient characteristics in the Finnish Prostate Cancer Screening Trial.</p

Overall cancer mortality and lag time analyses by amount, duration and intensity of non-steroidal anti-inflammatory drugs in the Finnish Prostate Cancer Screening Trial during 1996–2012.

<p>Overall cancer mortality and lag time analyses by amount, duration and intensity of non-steroidal anti-inflammatory drugs in the Finnish Prostate Cancer Screening Trial during 1996–2012.</p